View Older Stories View More Recent Stories
-
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
-
Jaguar Health (JAGX) Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
-
Jaguar Health (JAGX) phase 3 OnTarget trial did not meet its primary endpoint
-
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
-
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
-
Jaguar Health's (JAGX) Napo Receives New European & Australian Patents
-
Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs)
-
Jaguar Health (JAGX) Regains Compliance with Nasdaq's Bid Price Requirement
-
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
-
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
-
Jaguar Health (JAGX) Announces Approval of All Proposals at June 2024 Annual Meeting of Stockholders
-
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
-
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
